![François Liebaert](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
François Liebaert
Keine laufenden Positionen mehr
Karriereverlauf von François Liebaert
Ehemalige bekannte Positionen von François Liebaert
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Geschäftsführer | - | - |
INTEGRAGEN | Technik-/Wissenschafts-/F&E-Leiter | 22.09.2011 | - |
Ausbildung von François Liebaert
Université de Lille II | Doctorate Degree |
École des Hautes Études Commerciales de Paris | Masters Business Admin |
Statistik
International
Frankreich | 5 |
Operativ
Chief Tech/Sci/R&D Officer | 1 |
Doctorate Degree | 1 |
Masters Business Admin | 1 |
Sektoral
Consumer Services | 3 |
Health Services | 2 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INTEGRAGEN | Health Services |
Private Unternehmen | 1 |
---|---|
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | Health Technology |
- Börse
- Insiders
- François Liebaert
- Erfahrung